
AMERICAN ACADEMY™ OF OPHTHALMOLOGY

Protecting Sight. Empowering Lives.™

# IRIS® Clinical Data Registry American Academy of Ophthalmology

#### David W. Parke II, M.D. CEO



### IRIS: History and Scope: launched Jan 2014; FIGmd software vendor

#### Contracted

17,877 physicians from 5,195 practices


#### **Contracted for EHR Integration**

14,221 physicians from 2,903 practices

#### Number of patient visits


200 million, representing 48 million patients





## **IRIS Registry: Accomplishments**

- Quality Reporting: 11,612 providers for 2016; 0% error rate
  About 14,000 for 2017
- Data Analytics: performed in-house by registry staff
- Publications: 11 peer-reviewed papers in last 18 months
- Quality Improvement:
- Commercialization:
  - Licensed to DigiSight Technologies
    November 2017







## IRIS Registry—A Current Challenge: Managing Scientific Investigation

- Lots of enthusiasm by investigators for use of IRIS data in clinical real-world, large dataset investigation.
  - Natural history; disease prevalence; characterization of patient populations; practice patterns; clinical outcomes; risk factors; etc
- Lots of enthusiasm by traditional and nontraditional funding sources:
  - NIH; nonprofit vision research philanthropies; subspecialty societies; academic institutions
  - Academy and Academy members
- Need to set and implement standards and processes for proposal review, approval and prioritization; investigator qualification; data access (multiple approaches); funding requirements; project outcomes review; authorship; publication; and more



## IRIS Registry Innovation to Share: Approach to Commercialization

- IRIS was initiated as a quality of care improvement tool; remains its primary purpose
- Secondary purposes are quality reporting and generation of new science
- Ongoing problems: funding, data curation/integrity, analytic platforms/tools, integration of new data sets
- Commercialization can provide funds and expertise to address these problems
- Licensed commercialization to DigiSight Technologies after partner search
  - Agreement protects and enhances noncommercial activities
  - Project fully funded; already successful in commercial space

